Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Explore our online Annual Report 2024 summary Discover how we champion inclusion and diversity at AstraZeneca We have 191 projects in our pipeline View pipeline Learn about our cell therapy ambition ...
AstraZeneca will share updates from the Company’s innovative early oncology pipeline across multiple strategic platforms during the virtual American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021. Five presentations will unveil the next-generatio...
More global research and innovation programs will be introduced into China on the basis that the company has around 150 pipeline projects in China, among which 90 percent are progressing neck to neck with relevant global prog...
AstraZeneca is focused on strengthening its oncology business strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Oncology sales now comprise around 40% of AstraZeneca‘s total revenues and rose 17% in 2021, 19% in 2022...
AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio Breast Cancer Symposium (SABCS) on 7-10 December 2021. Fourteen AstraZeneca medicines and potential new medicines from the pipeline will be featured acros...
AstraZeneca Strengthens its Cardiovascular Pipeline with Agreement for a Pre-Clinical Novel Lipid-Lowering Therapy October 8, 2024 0 AstraZeneca Agreement with CSPC Pharmaceutical Group Yesterday, October 7, 2024, AstraZeneca (AZN) announced it entered into an exclusive license agreement with CSPC Pha...
The facility will incorporate state-of-the-art processing technologies and digital innovation to expedite the production of small molecules for high value-added medicines in AstraZeneca’s pipeline. The plant’s future-proof design will allow it to respond quickly to rapid changes in clinical and ...
AstraZeneca aims to create a “2.0” cancer pipeline and is giving ESMO-goers a peek at data for 3 of its bispecific antibody candidates.
juncture in its evolution,” said Dr. Kaplan. “I look forward to working with the team to strengthen key areas of the business, positioning the Company for sustained success. Our commitment to advancing the organization will give us the potential to develop a pipeline of transformative therapies...
AstraZeneca 於 2021 年 7 月開始使用 Amazon SageMaker Studio。「它包括部署、ML 操作、模型登錄檔、SageMaker Feature Store 以及將模型部署到不同階段或環境的能力,」Cabading 說。「我們可以直接在 Amazon SageMaker Studio 內自動進行大多數的 ML 開發程序,而不必建立許多人工作業程序。」...